Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial

Introduction Hepatocyte nuclear factor 1α (HNF1A)-diabetes is the most common monogenetic subtype of diabetes. Strict glycaemic control is crucial for a good prognosis for patients with HNF1A-diabetes. Sulfonylurea (SU) is used as a first-line therapy in HNF1A-diabetes. However, SU therapy may be pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Torben Hansen, Tina Vilsbøll, Filip Krag Knop, Alexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/8/10/e022517.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items